RESUMO
BACKGROUND: Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. METHODS: In this phase 3, double-blind, randomized trial, we assigned patients with hereditary, also known as variant, or wild-type ATTR cardiac amyloidosis, in a 1:1 ratio, to receive patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks for 12 months. A hierarchical procedure was used to test the primary and three secondary end points. The primary end point was the change from baseline in the distance covered on the 6-minute walk test at 12 months. The first secondary end point was the change from baseline to month 12 in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score (with higher scores indicating better health status). The second secondary end point was a composite of death from any cause, cardiovascular events, and change from baseline in the 6-minute walk test distance over 12 months. The third secondary end point was a composite of death from any cause, hospitalizations for any cause, and urgent heart failure visits over 12 months. RESULTS: A total of 360 patients were randomly assigned to receive patisiran (181 patients) or placebo (179 patients). At month 12, the decline in the 6-minute walk distance was lower in the patisiran group than in the placebo group (Hodges-Lehmann estimate of median difference, 14.69 m; 95% confidence interval [CI], 0.69 to 28.69; P = 0.02); the KCCQ-OS score increased in the patisiran group and declined in the placebo group (least-squares mean difference, 3.7 points; 95% CI, 0.2 to 7.2; P = 0.04). Significant benefits were not observed for the second secondary end point. Infusion-related reactions, arthralgia, and muscle spasms occurred more often among patients in the patisiran group than among those in the placebo group. CONCLUSIONS: In this trial, administration of patisiran over a period of 12 months resulted in preserved functional capacity in patients with ATTR cardiac amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO-B ClinicalTrials.gov number, NCT03997383.).
Assuntos
Amiloidose , Cardiomiopatias , Pré-Albumina , RNA Interferente Pequeno , Humanos , Cardiomiopatias/tratamento farmacológico , Cardiomiopatias/etiologia , Cardiomiopatias/genética , Cardiomiopatias/metabolismo , Pré-Albumina/genética , Pré-Albumina/metabolismo , RNA Interferente Pequeno/uso terapêutico , Amiloidose Familiar/complicações , Amiloidose Familiar/tratamento farmacológico , Amiloidose Familiar/genética , Fígado/metabolismo , Método Duplo-Cego , Amiloidose/complicações , Amiloidose/tratamento farmacológico , Amiloidose/genéticaRESUMO
Macular amyloidosis (MA) is a common form of cutaneous amyloidosis that manifests as dark spots consisting of brown pigments with a rippled pattern on the skin, and the treatment of this condition is highly challenging. The aim of this study was to compare the efficacy and safety of intralesional injection of tranexamic acid (TXA) and topical application of Kligman combination drug in the treatment of macular amyloidosis. In this double-blind clinical trial, a total of 43 patients, who were diagnosed with MA, were treated with two different methods of intralesional injection of tranexamic acid and topical application of Kligman combination drug. Both therapeutic methods were effective in improving MA and significantly reduced hyperpigmentation of the treated areas, but tranexamic acid was significantly more effective than the Kligman combination drug. Significantly, greater improvements were observed in the group of patients treated with tranexamic acid. In the tranexamic acid treatment group, ΔE was reduced from 11.39 in the first session to 8.53 in the third session, and in the Kligman treatment group, it was reduced from 8.79 in the first session to 6.32 in the third session (p < 0.05). In addition, the pruritus score in patients treated with topical tranexamic acid injection was lower compared to the patients treated with the topical application of the Kligman combination drug. The results of this study demonstrated the significant positive effects of both treatment methods, but in terms of reducing melanin content, intralesional injection of tranexamic acid was a more effective method. Both treatments considered safe for MA. In tranexamic acid group, patients logically experienced a tolerable pain during injection but they significantly had significantly lower local pruritic discomfort during study. So, based on the positive findings of this study we suggest to use tranexamic acid in combination with other effective therapeutic methods for treatment of MA especially use of its topically applied form in combination with non-aggressive needling that results in better drug delivery without the experience of injection pain. Selection of the best administration route of tranexamic acid for hyperpigmented lesions depends on the each patient characteristic and their previous theraputic results that may vary case by case.
Assuntos
Amiloidose Familiar , Hiperpigmentação , Dermatopatias Genéticas , Ácido Tranexâmico , Administração Tópica , Amiloidose Familiar/tratamento farmacológico , Humanos , Hiperpigmentação/induzido quimicamente , Injeções Intralesionais , Dermatopatias Genéticas/tratamento farmacológicoRESUMO
The liver-derived, circulating transport protein transthyretin (TTR) is the cause of systemic hereditary (ATTRv) and wild-type (ATTRwt) amyloidosis. TTR stabilization and knockdown are approved therapies to mitigate the otherwise lethal disease course. To date, the variety in phenotypic penetrance is not fully understood. This systematic review summarizes the current literature on TTR pathophysiology with its therapeutic implications. Tetramer dissociation is the rate-limiting step of amyloidogenesis. Besides destabilizing TTR mutations, other genetic (RBP4, APCS, AR, ATX2, C1q, C3) and external (extracellular matrix, Schwann cell interaction) factors influence the type of onset and organ tropism. The approved small molecule tafamidis stabilizes the tetramer and significantly decelerates the clinical course. By sequence-specific mRNA knockdown, the approved small interfering RNA (siRNA) patisiran and antisense oligonucleotide (ASO) inotersen both significantly reduce plasma TTR levels and improve neuropathy and quality of life compared to placebo. With enhanced hepatic targeting capabilities, GalNac-conjugated siRNA and ASOs have recently entered phase III clinical trials. Bivalent TTR stabilizers occupy both binding groves in vitro, but have not been tested in trials so far. Tolcapone is another stabilizer with the potential to cross the blood-brain barrier, but its half-life is short and liver failure a potential side effect. Amyloid-directed antibodies and substances like doxycycline aim at reducing the amyloid load, however, none of the yet developed antibodies has successfully passed clinical trials. ATTR-amyloidosis has become a model disease for pathophysiology-based treatment. Further understanding of disease mechanisms will help to overcome the remaining limitations, including application burden, side effects, and blood-brain barrier permeability.
Assuntos
Amiloidose Familiar/tratamento farmacológico , Amiloidose Familiar/genética , Pré-Albumina/efeitos dos fármacos , Amiloide/antagonistas & inibidores , Amiloide/biossíntese , Amiloide/genética , Amiloidose Familiar/fisiopatologia , Animais , Técnicas de Silenciamento de Genes , Humanos , Pré-Albumina/genéticaRESUMO
Lichen amyloidosis is a subtype of primary localized cutaneous amyloidosis characterized by deposition of amyloid protein in the skin without visceral involvement. Although it is usually limited to localized areas of the body, it rarely can present in a generalized fashion and is severely pruritic. The limited form is treated with skin directed therapies such as topical or intralesional corticosteroids or topical tacrolimus but the generalized type is more difficult to treat. We present a patient with generalized primary cutaneous lichen amyloidosis successfully treated with dupilumab.
Assuntos
Amiloidose Familiar/tratamento farmacológico , Anticorpos Monoclonais Humanizados/uso terapêutico , Dermatopatias Genéticas/tratamento farmacológico , Idoso , Amiloidose Familiar/complicações , Amiloidose Familiar/patologia , Humanos , Injeções Subcutâneas , Masculino , Prurido/etiologia , Pele/patologia , Dermatopatias Genéticas/complicações , Dermatopatias Genéticas/patologiaAssuntos
Amiloidose Familiar/complicações , Dermatopatias Genéticas/complicações , Corticosteroides/uso terapêutico , Amiloidose Familiar/tratamento farmacológico , Amiloidose Familiar/patologia , Exantema/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prurido/etiologia , Dermatopatias Genéticas/tratamento farmacológico , Dermatopatias Genéticas/patologiaAssuntos
Amiloidose Familiar/diagnóstico , Anti-Inflamatórios/uso terapêutico , Clobetasol/uso terapêutico , Dermatopatias Genéticas/diagnóstico , Adulto , Amiloidose Familiar/tratamento farmacológico , Amiloidose Familiar/patologia , Anti-Inflamatórios/administração & dosagem , Braço , Clobetasol/administração & dosagem , Diagnóstico Diferencial , Feminino , Humanos , Dermatopatias Genéticas/tratamento farmacológico , Dermatopatias Genéticas/patologiaAssuntos
Amiloidose Familiar/complicações , Herpes Zoster/complicações , Hipo-Hidrose/etiologia , Líquen Plano/complicações , Dermatopatias Genéticas/complicações , Administração Tópica , Adulto , Amiloidose Familiar/tratamento farmacológico , Amiloidose Familiar/patologia , Biópsia por Agulha , Fármacos Dermatológicos/uso terapêutico , Seguimentos , Herpes Zoster/tratamento farmacológico , Herpes Zoster/patologia , Humanos , Hipo-Hidrose/tratamento farmacológico , Hipo-Hidrose/fisiopatologia , Imuno-Histoquímica , Líquen Plano/tratamento farmacológico , Líquen Plano/patologia , Masculino , Doenças Raras , Medição de Risco , Estudos de Amostragem , Dermatopatias Genéticas/tratamento farmacológico , Dermatopatias Genéticas/patologia , Resultado do TratamentoAssuntos
Amiloidose Familiar/história , Artrite Juvenil/história , Adolescente , Amiloidose Familiar/sangue , Amiloidose Familiar/tratamento farmacológico , Amiloidose Familiar/etiologia , Artrite Juvenil/complicações , Artrite Juvenil/tratamento farmacológico , Criança , Feminino , História do Século XX , Humanos , Proteína Amiloide A SéricaAssuntos
Amiloidose Familiar/tratamento farmacológico , Imunossupressores/uso terapêutico , Metotrexato/uso terapêutico , Dermatopatias Genéticas/tratamento farmacológico , Pele/efeitos dos fármacos , Idoso , Amiloidose Familiar/diagnóstico , Amiloidose Familiar/imunologia , Substituição de Medicamentos , Humanos , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Pele/imunologia , Pele/patologia , Dermatopatias Genéticas/diagnóstico , Dermatopatias Genéticas/imunologia , Resultado do TratamentoRESUMO
RATIONALE: Primary cutaneous amyloidosis (PCA) is a localized skin disorder characterized by the abnormal deposition of amyloid in the extracellular matrix of the dermis. The association between PCA and other diseases, although rare, has been documented for various autoimmune diseases. PCA associated with autoimmune hepatitis-primary biliary cirrhosis (AIH-PBC) overlap syndrome and Sjögren syndrome (SS) has not been previously reported in the literature. PATIENT CONCERNS: A 50-year-old woman presented with progressive abnormal liver enzyme levels and was referred to our department. DIAGNOSES: Due to the patient's symptoms, laboratory test results, radiographic findings, and pathologic results, she was diagnosed with PCA associated with AIH-PBC overlap syndrome and SS. INTERVENTIONS: She was subsequently treated with a combination of ursodeoxycholic acid (UDCA), prednisone, and azathioprine. OUTCOMES: While this treatment can achieve therapeutic success, it cannot prevent complications from cirrhosis. This patient remains alive but experienced an emergent gastrointestinal hemorrhage. LESSONS: While we acknowledge that this is a single case, these findings extend our knowledge of immunological diseases associated with PCA and suggest a common, immune-mediated pathogenic pathway between PCA, AIH-PBC overlap syndrome, and SS. After 12 years of follow up, clinical manifestations have developed, and these autoimmune diseases have progressed. The combination of UDCA, prednisone, and azathioprine can achieve therapeutic success but cannot prevent disease progression. Routine follow up for this patient is necessary to document disease progression.
Assuntos
Amiloidose Familiar/imunologia , Hepatite Autoimune/complicações , Cirrose Hepática Biliar/complicações , Síndrome de Sjogren/complicações , Dermatopatias Genéticas/imunologia , Doenças do Tecido Conjuntivo Indiferenciado/complicações , Amiloidose Familiar/tratamento farmacológico , Anti-Inflamatórios/administração & dosagem , Azatioprina/administração & dosagem , Colagogos e Coleréticos/administração & dosagem , Quimioterapia Combinada , Feminino , Hepatite Autoimune/tratamento farmacológico , Hepatite Autoimune/imunologia , Humanos , Imunossupressores/administração & dosagem , Cirrose Hepática Biliar/tratamento farmacológico , Cirrose Hepática Biliar/imunologia , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Síndrome de Sjogren/tratamento farmacológico , Síndrome de Sjogren/imunologia , Dermatopatias Genéticas/tratamento farmacológico , Resultado do Tratamento , Doenças do Tecido Conjuntivo Indiferenciado/tratamento farmacológico , Doenças do Tecido Conjuntivo Indiferenciado/imunologia , Ácido Ursodesoxicólico/administração & dosagemRESUMO
Macular amyloidosis (MA) represents a common variant of primary localized cutaneous amyloidosis. It has a characteristic female predominance; none of the treatment modalities described is either curative or uniformly effective in patients with macular amyloidosis. To determine the effect of fractional CO2 laser in macular amyloidosis in comparison to fractional CO2 laser-assisted drug delivery of topical steroids and topical vitamin C, the study includes 10 female patients with cutaneous macular amyloidosis aged between 20 and 62 years. Patients were treated with four sessions of fractional CO2 laser with 4 weeks interval. Laser treatments were performed using fractional CO2 laser with the following parameters (power 18 W, spacing 800 µm, dwell time 600 µs, stacking 3). The lesion is divided into three areas: area 1, treated by fractional laser only; area 2, treated by fractional laser followed by topical corticosteroid application under occlusion for 24 h; and area 3, treated by fractional laser followed by topical vitamin C serum application under occlusion for 24 h. All lesions were examined clinically and histologically before the therapy and 1 month after the end of the therapy to evaluate the degree of improvement. All treated areas show significant decrease in pigmentation score after treatment, significant drop in rippling (P value < 0.016), and improvement of lichenification; as regards the histological improvement, there was a significant decrease of the amyloid amount after treatment. As regards the amyloid amount, results show significant decrease in the amount of amyloid in all of the three treated areas. Area 2 reported the highest decrease in the amyloid amount followed by areas 1 and 3. One patient (10%) was highly satisfied by the treatment, 6 (60%) reported moderate degree of satisfaction, while only 3 (30%) reported mild satisfaction. Minimal complication occurred in the form of post-inflammatory hyperpigmentation in 1 patient. None of the patients suffered pain, ulceration, or infection. Fractional CO2 alone can be used to improve the texture of macular amyloidosis. If used to assist the delivery of topical steroids and topical vitamin C, improvement can be highly increased.
Assuntos
Amiloidose Familiar/radioterapia , Ácido Ascórbico/administração & dosagem , Valerato de Betametasona/administração & dosagem , Glucocorticoides/administração & dosagem , Lasers de Gás/uso terapêutico , Dermatopatias Genéticas/radioterapia , Administração Tópica , Adulto , Amiloidose Familiar/tratamento farmacológico , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Dermatopatias Genéticas/tratamento farmacológico , Pigmentação da Pele , Resultado do Tratamento , Adulto JovemRESUMO
Lichen amyloidosis (LA) is characterized by the deposition of amyloid that may respond to chronic scratching that may be secondary to atopic dermatitis, stasis dermatitis, or interface dermatitis. Despite the development of several therapeutic strategies, including topical steroids, oral antihistamines, cyclosporine, and retinoids, an effective treatment for LA has not been established. A 49-year-old woman who has been treated irregularly for atopic dermatitis for 7 years presented with localized brownish papules on the left forearm and right elbow. They developed 3 months prior and were becoming more prominent despite of treatment with cyclosporine, oral antihistamines, and topical steroids for 5 months prior to presentation. A skin biopsy revealed amyloid deposition in the dermal papillae and the patient was diagnosed with LA associated with atopic dermatitis. A 6-month course of daily oral alitretinoin 30 mg produced marked improvement in the thickness and color of the hyperkeratotic papules without aggravation of the patient's atopic dermatitis. Histologic evaluation showed clearance of amyloid deposition and almost normalization of the epidermal changes. Herein, we report a case of LA treated with alitretinoin and suggest that it could be a potential treatment option for LA, especially in patients with inflammatory skin diseases including atopic dermatitis.
Assuntos
Amiloidose Familiar/tratamento farmacológico , Fármacos Dermatológicos/administração & dosagem , Dermatopatias Genéticas/tratamento farmacológico , Pele/efeitos dos fármacos , Tretinoína/administração & dosagem , Administração Oral , Alitretinoína , Amiloidose Familiar/diagnóstico , Biópsia , Feminino , Humanos , Pessoa de Meia-Idade , Indução de Remissão , Pele/patologia , Dermatopatias Genéticas/diagnóstico , Resultado do TratamentoRESUMO
Primary localized cutaneous amyloidosis is a skin-limited amyloidosis that does not involve internal organs. It is clinically subclassified into 3 general categories and some rare variants. However, there is considerable overlap within the classification. Though there are a variety of therapeutic measures, the treatment is often unsatisfactory, particularly when the disease is severe and extensive. We describe a rare case of primary localized cutaneous amyloidosis with lichen and poikiloderma-like lesions that showed an excellent response to systemic acitretin.
Assuntos
Acitretina/uso terapêutico , Amiloidose Familiar/tratamento farmacológico , Ceratolíticos/uso terapêutico , Dermatopatias Genéticas/tratamento farmacológico , Amiloidose Familiar/complicações , Amiloidose Familiar/diagnóstico , Feminino , Humanos , Erupções Liquenoides/complicações , Erupções Liquenoides/tratamento farmacológico , Dermatopatias Genéticas/complicações , Dermatopatias Genéticas/diagnóstico , Resultado do Tratamento , Adulto JovemRESUMO
Abstract: Primary localized cutaneous amyloidosis is a skin-limited amyloidosis that does not involve internal organs. It is clinically subclassified into 3 general categories and some rare variants. However, there is considerable overlap within the classification. Though there are a variety of therapeutic measures, the treatment is often unsatisfactory, particularly when the disease is severe and extensive. We describe a rare case of primary localized cutaneous amyloidosis with lichen and poikiloderma-like lesions that showed an excellent response to systemic acitretin.
Assuntos
Humanos , Feminino , Adulto Jovem , Dermatopatias Genéticas/tratamento farmacológico , Acitretina/uso terapêutico , Amiloidose Familiar/tratamento farmacológico , Ceratolíticos/uso terapêutico , Dermatopatias Genéticas/complicações , Dermatopatias Genéticas/diagnóstico , Resultado do Tratamento , Erupções Liquenoides/complicações , Erupções Liquenoides/tratamento farmacológico , Amiloidose Familiar/complicações , Amiloidose Familiar/diagnósticoAssuntos
Amiloidose Familiar/tratamento farmacológico , Amiloidose Familiar/patologia , Isotretinoína/uso terapêutico , Dermatopatias Genéticas/tratamento farmacológico , Dermatopatias Genéticas/patologia , Administração Oral , Adulto , Amiloidose Familiar/diagnóstico , Biópsia por Agulha , Doença Crônica , Diagnóstico Diferencial , Feminino , Seguimentos , Humanos , Imuno-Histoquímica , Prurido/diagnóstico , Prurido/etiologia , Dermatopatias Genéticas/diagnóstico , Resultado do TratamentoRESUMO
Amyloid deposition in the pituitary gland is a rare localised form of amyloidosis, and most commonly reported with prolactinoma. Macular amyloidosis is a rare form of localised cutaneous amyloidosis of obscure aetiology. In contrast to most localised amyloidosis, the precursor protein(s) of both macular amyloidosis and prolactinoma are unknown. A 35-year-old man with chronic headache (six years), blurring of vision (three years), and hyperpigmented macular lesion involving arms, legs, and back (two years) was diagnosed to have hyperprolactinaemia (8927 ng/mL) and secondary adrenal insufficiency. MRI revealed pituitary macroadenoma compressing the optic chiasma, encasing the right carotid artery and extending into the sphenoid sinus. A biopsy of skin from the right upper arm revealed thickened stratum corneum, acanthosis, and deposition of pale eosinophilic material in papillary dermis that gave a rose pink colour under methyl-violet and appeared congophilic with Congo red stain, which under polarised light showed green birefringence, diagnostic of macular amyloidosis. Headache, bitemporal haemianopia, and skin lesion improved following cabergoline therapy. Temporal profile of the disease characterised by symptoms of macroprolactinoma preceding onset of macular amyloidosis with resolution of symptoms of macroprolactinoma, accompanied by reductions in prolactin, and concomitant improvement in macular amyloidosis with cabergoline therapy may suggest some link between macroprolactinoma and macular amyloidosis. This report intends to highlight this novel association of macular amyloidosis and macroprolactinoma.